000 03445nam a22004575i 4500
001 978-1-4471-4297-3
003 DE-He213
005 20140220082805.0
007 cr nn 008mamaa
008 121026s2013 xxk| s |||| 0|eng d
020 _a9781447142973
_9978-1-4471-4297-3
024 7 _a10.1007/978-1-4471-4297-3
_2doi
050 4 _aRC681-688.2
072 7 _aMJD
_2bicssc
072 7 _aMED010000
_2bisacsh
082 0 4 _a616.12
_223
100 1 _aFerro, Albert.
_eeditor.
245 1 0 _aAntiplatelet and Anticoagulation Therapy
_h[electronic resource] /
_cedited by Albert Ferro, David A. Garcia.
264 1 _aLondon :
_bSpringer London :
_bImprint: Springer,
_c2013.
300 _aX, 247 p. 37 illus., 26 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aCurrent Cardiovascular Therapy
505 0 _aAntiplatelet agents: current and novel -- Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring -- Anticoagulant Drugs: Current and Novel -- Primary prevention of cardiovascular disease -- Approaches to the Prophylaxis and Treatment of Venous and Cardiac Thromboembolic Disease.
520 _aAspirin has been in clinical use for over 100 years, making it one of the oldest commonly used drugs in medicine, and is now predominantly used as an antiplatelet agent. Major new antiplatelet drug classes have recently become available for the clinician that offer the promise of major improvements in the treatment and prevention of arterial thrombotic disease. In the field of anticoagulation, the vitamin K antagonists such as warfarin have not been available for as long as aspirin in the antiplatelet field, and have also had very little in the way of competition until recently; although a number of parenteral anticoagulants have been available, the vitamin K antagonists have been the only orally active anticoagulant drugs. The last few years have seen the arrival of new drug classes, the orally active direct thrombin inhibitors and factor Xa antagonists, which offer a number of advantages, but not without important drawbacks. In the face of these important advances in both antiplatelet and anticoagulant therapy, clinicians often feel confused, even overwhelmed, as to what is now available and which drugs are useful (and indicated) in which circumstances. Antiplatelet and Anticoagulant Therapy is designed with such people in mind. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
650 0 _aMedicine.
650 0 _aCardiology.
650 1 4 _aMedicine & Public Health.
650 2 4 _aCardiology.
650 2 4 _aMedicine/Public Health, general.
700 1 _aGarcia, David A.
_eeditor.
710 2 _aSpringerLink (Online service)
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9781447142966
830 0 _aCurrent Cardiovascular Therapy
856 4 0 _uhttp://dx.doi.org/10.1007/978-1-4471-4297-3
912 _aZDB-2-SME
999 _c94585
_d94585